Thrombopoietin and steroid combo frontline treatment for ITP patients: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2020-09-16 11:45 GMT | Update On 2020-09-16 11:45 GMT
Advertisement
China: The addition of recombinant human thrombopoietin (rhTPO) to high-dose dexamethasone (HD-DXM) results in higher response rates, causing more durable responses in immune thrombocytopenia (ITP) patients, suggests a recent study. The study is published in the American Journal of Hematology.
Yafei Yu, Cheeloo College of Medicine Shandong University, Jinan, Shandong, China, and colleagues compare the efficacy and safety of HD-DXM plus recombinant rhTPO versus HD-DXM alone in newly diagnosed adult ITP patients.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.